TWi Biotechnology, Inc.
TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; and AC- 1101, which is in Phase 1 trial fo… Read more
TWi Biotechnology, Inc. (6610) - Total Liabilities
Latest total liabilities as of June 2025: NT$124.72 Million TWD
Based on the latest financial reports, TWi Biotechnology, Inc. (6610) has total liabilities worth NT$124.72 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
TWi Biotechnology, Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how TWi Biotechnology, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
TWi Biotechnology, Inc. Competitors by Total Liabilities
The table below lists competitors of TWi Biotechnology, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ebebek Magazacilik Anonim Sirketi
IS:EBEBK
|
Turkey | TL10.06 Billion |
|
ELUON Corporation
KQ:065440
|
Korea | ₩24.94 Billion |
|
ENGIE Eps S.A
F:8XE
|
Germany | €300.64 Million |
|
Pacific Century Premium Developments Limited
PINK:PCPDF
|
USA | $11.31 Billion |
|
Acarix AB (publ)
OTCQB:ACIXF
|
USA | $3.62 Million |
|
Mohenz.Co.Ltd
KQ:006920
|
Korea | ₩19.16 Billion |
|
Benfica
LS:SLBEN
|
Portugal | €483.36 Million |
|
Wheels Up Experience Inc
NYSE:UP
|
USA | $1.35 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down TWi Biotechnology, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TWi Biotechnology, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TWi Biotechnology, Inc. (2019–2024)
The table below shows the annual total liabilities of TWi Biotechnology, Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$66.47 Million | +19.10% |
| 2023-12-31 | NT$55.81 Million | +96.59% |
| 2022-12-31 | NT$28.39 Million | -11.94% |
| 2021-12-31 | NT$32.24 Million | -65.31% |
| 2020-12-31 | NT$92.93 Million | +1690.50% |
| 2019-12-31 | NT$5.19 Million | -- |